RxDoctor Payments Data

Robert Anderson, MD

Internal Medicine · Anderson, INNPI 1790851509

Payments from drug & device makers

$10,809in general payments, 2019–2025

Across 756 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$972
  • Johnson & Johnson$619
  • Bayer$606
  • plus $5K from 32 others

What the payments were for

  • Food & beverage$10,56798%
  • Education$2422%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,809 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$136,629
Medicare patients
528
Services billed
1,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban502$264,136
OzempicSemaglutide130$177,064
JardianceEmpagliflozin107$130,777
FarxigaDapagliflozin Propanediol110$98,326
XareltoRivaroxaban114$52,276
LinzessLinaclotide44$50,496
JanuviaSitagliptin Phosphate40$49,597
TrulicityDulaglutide35$45,522
RybelsusSemaglutide26$44,735
TradjentaLinagliptin98$39,253
EntrestoSacubitril/Valsartan67$36,533
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$35,122
MyrbetriqMirabegron63$31,965
MounjaroTirzepatide26$29,847
TrintellixVortioxetine Hydrobromide30$21,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$379$269,747517 claims
Novo NordiskOzempic, Rybelsus$1,507$221,799156 claims
Boehringer IngelheimJardiance, Tradjenta$312$170,030205 claims
AstraZenecaFarxiga$1,201$98,326110 claims
Lilly USA, LLCTrulicity, Mounjaro$972$75,36861 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$581$68,75588 claims
Johnson & JohnsonXarelto$619$52,276114 claims
AbbVieLinzess$1,290$50,49644 claims
MerckJanuvia$198$49,59740 claims
NovartisEntresto$444$36,53367 claims
Astellas Pharma US IncMyrbetriq$337$31,96563 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$204$21,18630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →